AxoGen, Stock Of The Day, Offers Entry After Bullish Rebound
AxoGen Says Nerve Repair Strategy Intact as Reimbursement Wins Gather Steam
Axogen, Inc. (AXGN) Presents at Bank of America Global Healthcare Conference 2026 Prepared Remarks Transcript
Axogen, Inc. to Participate in the 2026 Bank of America Global Healthcare Conference
Axogen, Inc. (AXGN) Q1 2026 Earnings Call Transcript
AxoGen (AXGN) Q1 Earnings Lag Estimates
Axogen, Inc. Reports First Quarter 2026 Financial Results
Capricorn Fund Makes a Huge Bet on Nerve Repair With 687,000 Share Axogen (AXGN) Investment Worth $22.4 Million
AxoGen (AXGN) Reports Next Week: Wall Street Expects Earnings Growth
AxoGen (AXGN) Surges 7.5%: Is This an Indication of Further Gains?
Axogen, Inc. to Report First Quarter 2026 Financial Results on April 28, 2026
SG Americas Securities LLC Increases Stock Holdings in AxoGen, Inc. $AXGN
AxoGen, Inc. $AXGN Shares Sold by JPMorgan Chase & Co.
Exchange Traded Concepts LLC Sells 26,743 Shares of AxoGen, Inc. $AXGN
Axogen Insider Sale of 5,221 Shares Follows 20% Revenue Growth in 2025. Here's What to Know
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
ArrowMark Colorado Holdings LLC Buys 332,498 Shares of AxoGen, Inc. $AXGN
AxoGen Says BLA Approval Secures Avance Use, Boosts Coverage Talks and Reimbursement Momentum
AxoGen Touts FDA BLA Win, Targets 18% Growth and Wider Nerve Repair Adoption at Raymond James Conference
Axogen, Inc. (AXGN) Presents at 47th Annual Raymond James Institutional Investor Conference Transcript
Axogen Q4: EPS Miss Amid Biologics Transition
Axogen, Inc. (AXGN) Q4 2025 Earnings Call Transcript
AxoGen (AXGN) Q4 Earnings Miss Estimates
HighMark Wealth Management Buys 158,855 Shares of Axogen Stock
First Eagle Small Cap Opportunity Fund Q4 2025 Portfolio Review
Principal Financial Group Inc. Purchases 21,002 Shares of AxoGen, Inc. $AXGN
Axogen, Inc. to Participate in Multiple Upcoming Investor Conferences
Axogen, Inc. to Report Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Wasatch Micro Cap Fund Q4 2025 Performance Review
Axogen Announces Pricing of Upsized $124 Million Public Offering of Common Stock
Axogen Announces Proposed Public Offering of Common Stock
Axogen, Inc. (AXGN) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Axogen CEO Axed 25,000 Shares From His Direct Holdings
Axogen, Inc. Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2025
Assenagon Asset Management S.A. Grows Stake in AxoGen, Inc. $AXGN
Axogen Announces FDA Approval of Biologics License Application for AVANCE® (acellular nerve allograft–arwx)
FDA approves Axogen's nerve repair graft
Avance Nerve Graft FDA Verdict Approaches, Why Investors Are Watching Axogen
Wasatch Micro Cap Value Fund Q3 2025 Contributors And Detractors
Axogen, Inc. (AXGN) Q3 2025 Earnings Call Transcript
AxoGen (AXGN) Q3 Earnings and Revenues Top Estimates
Axogen, Inc. Reports Third Quarter 2025 Financial Results
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
Axogen, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights – AXGN
AXGN Investors Have Opportunity to Join Axogen, Inc. Fraud Investigation with the Schall Law Firm
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Axogen, Inc. - AXGN